

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

---

Date of Report (Date of earliest event reported): March 29, 2016

**PROPHASE LABS, INC.**

(Exact name of Company as specified in its charter)

---

**Delaware**

(State or other  
jurisdiction of incorporation)

---

**0-21617**

(Commission  
File Number)

---

**23-2577138**

(I.R.S. Employer  
Identification No.)

**621 N. Shady Retreat Road  
Doylestown, PA**  
(Address of principal executive offices)

**18901**  
(Zip Code)

Company's telephone number, including area code: **(215) 345-0919**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 2.02 Results of Operations and Financial Condition.**

On March 29, 2016, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the three months and year ended December 31, 2015. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<u>No.</u>	<u>Description</u>
99.1	Press Release dated March 29, 2016

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ProPhase Labs, Inc.**

By: /s/ Robert V. Cuddihy, Jr.

Robert V. Cuddihy, Jr.  
Chief Operating Officer and  
Chief Financial Officer

Date: March 29, 2016

---

INDEX TO EXHIBITS

Number	Description
99.1	Press Release issued March 29, 2016

---





**ProPhase Labs Reports Financial Results  
for the Fourth Quarter and Year Ended December 31, 2015**

DOYLESTOWN, Pennsylvania – March 29, 2016. **ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com)** today reported its net sales were \$8.2 million for the three months ended December 31, 2015, as compared to net sales of \$9.0 for the three months ended December 31, 2014. The Company incurred a net loss for the three months ended December 31, 2015 of \$1.3 million, or (\$0.07) per share, compared to a net loss of \$676,000, or (\$0.05) per share, for the three months ended December 31, 2014.

The Company's sales are principally derived from its over-the-counter ("OTC") health care and cold remedy products. As a consequence, a significant portion of our business is highly seasonal, which causes significant variations in operating results from quarter to quarter.

Results for the fourth quarter of 2015 compared to the fourth quarter of 2014 principally reflect the net effect of (i) a decrease in net sales of \$809,000 due to a decrease in shipments, (ii) an increase in administration costs of \$237,000 due principally to an increase in professional and legal costs and (iii) a decrease in sales and marketing expenses of \$764,000.

The Company generated net sales for the year ended December 31, 2015 of \$20.6 million, as compared to \$22.1 million for the year ended December 31, 2014. The Company incurred a net loss for the year ended December 31, 2015 of \$3.6 million, or (\$0.22) per share, compared to a net loss of \$7.8 million, or (\$0.47) per share, for the year ended December 31, 2014.

The financial results for the year ended December 31, 2015 as compared to the year ended December 31, 2014 reflect the net effect of (i) a decrease in net sales of \$1.5 million principally due to (a) a decrease in shipments and lower consumer demand as a consequence of several factors including the decrease in the incidence and severity of upper respiratory illness, offset by (b) a \$1.0 million increase in contract manufacturing operations, (ii) a decrease in administration costs of \$1.2 million due principally to a decrease in professional and legal costs related to certain, now resolved, litigation matters, (iii) a decrease in sales and marketing expenses of \$1.3 million as a consequence of a reduction from period to period of the timing and scope of our marketing initiatives, (iv) a decrease in research and development expenditures of \$244,000 and (v) a non-recurring impairment charge to operations of \$3.6 million during the third quarter of 2014. According to IMS Health (a healthcare industry information provider), key industry statistics reveal that the incidence of upper respiratory illness across the country has been down 12.6% for the period September through December 2015 as compared to the prior year September through December 2014. The category of cough and cold product sales, including our Cold-EEZE<sup>®</sup> sales, are highly correlated to the incidence of upper respiratory illness.

Ted Karkus, the CEO of the Company, stated, "Our product development efforts over the past several years have been largely focused on successfully leveraging the Cold-EEZE<sup>®</sup> brand. In order to grow our share of the cold remedy category, in February 2016, at the Efficient Collaborative Retail Marketing ("ECRM") industry trade conference and other related meetings, we met with approximately 80 important retailers and introduced to the trade additional, new and innovative Cold-EEZE<sup>®</sup> branded products that will continue to broaden and strengthen our cough/cold product line. Our research and development of new products in the cough/cold category has been robust."

Mr. Karkus continued, "In addition to the continued development and commercialization of new Cold-EEZE<sup>®</sup> branded products, we are also preparing to launch a new line of products in the dietary supplement category. In order to offset the seasonality of our current revenues and our dependence on the severity of the cold season, we are launching a new product line of over the counter, dietary supplements that will leverage our existing infrastructure, retail relationships and sales force. Following approximately 2-1/2 years of successful development, we are making our first foray into the dietary supplements category with the launch of our new line of TK Supplements<sup>TM</sup>."

Mr. Karkus added, “Our first new product is Legendz XL™, a men’s dietary supplement in the male enhancement category. After extensive research and preparation, we have produced our first set of direct response television spots and begun TV media testing. We have developed an integrated network of strategic vendors including a call center and a fulfillment center as well as the online infrastructure to execute a direct to consumer marketing and sales strategy. Our new Legendz XL™ website is now live: [www.LegendzXL.com](http://www.LegendzXL.com). We expect to continually refine our consumer engagement, TV spots, TV media plan and websites during the first half of fiscal 2016 and thereafter in order to optimize consumer response and generate product awareness. As with any new product launch, we anticipate losses from the TK Supplements™ initiatives as we optimize our direct response strategy.”

Mr. Karkus further stated, “Over time, our goal is for TK Supplements™ results to improve, which will lead to increasing the media spend which will, in turn, broaden brand awareness for our new line of products. As brand awareness increases, our next goal will be to introduce Legendz XL™ in retail stores, leveraging our existing infrastructure and retail distribution platform. We also have developed additional dietary supplements for future introduction at the appropriate time.”

Mr. Karkus concluded, “We are committed to executing a long term strategy to grow our Cold-EEZE® brand and to grow the Company by participating in the large dietary supplement category.”

A conference call will be held this morning, March 29<sup>th</sup>, at 11:00am EST. ProPhase Labs Chairman and CEO, Ted Karkus, and COO/CFO Robert Cuddihy will provide a company overview including a review of activities and fourth quarter results. There will be a question and answer session following initial remarks.

The conference call will be webcast live at:

<https://engage.vevent.com/rt/prophaselabsincao-032916> at 11:00 AM (EDT) on Tuesday, March 29, 2016.

Participants wishing to ask questions may access the live call by dialing (844) 301-0501 conference ID # 76794886A replay of the conference call will be available for 90 days on the company website [www.ProPhaseLabs.com](http://www.ProPhaseLabs.com).

##

#### **About ProPhase Labs**

ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE® cold remedy brand as well as other cold and flu relief products. Cold-EEZE® cold remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold. Cold-EEZE® cold remedy customers include leading national chain, regional, specialty and local retail stores. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE® cold remedy lozenges and fulfill other contract manufacturing opportunities. For more information visit us at [www.ProPhaseLabs.com](http://www.ProPhaseLabs.com).

#### **Forward Looking Statements**

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the launch of our new line of TK Supplements™, and our new product Legendz XL™. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to: the difficulty of predicting the acceptance and demand for our products, the impact of competitive products and pricing, costs involved in the manufacture and marketing of products, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.

#### **Press Only Contact**

Constantine Panagiotatos  
DKC Public Relations P  
Tel: (212) 981-5124  
[ConstantinePanagiotatos@dkcnews.com](mailto:ConstantinePanagiotatos@dkcnews.com)

#### **Investor Contact**

Ted Karkus, Chairman and CEO  
ProPhase Labs, Inc.  
(215) 345-0919 x 0

**PROPHASE LABS, INC. & SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(in thousands, except per share amounts)

	Three Months Ended		Year Ended	
	December 31, 2015 (unaudited)	December 31, 2014 (unaudited)	December 31, 2015	December 31, 2014
Net sales	\$ 8,163	\$ 8,972	\$ 20,604	\$ 22,070
Cost of sales	3,375	3,076	8,426	7,891
Gross profit	4,788	5,896	12,178	14,179
Operating expenses:				
Sales and marketing	3,476	4,240	7,698	8,965
Administration	2,152	1,915	6,986	8,143
Research and development	403	415	1,078	1,322
Impairment charge	-	-	-	3,577
	6,031	6,570	15,762	22,007
Loss from operations	(1,243)	(674)	(3,584)	(7,828)
Interest income, net	(13)	(2)	(16)	(6)
Loss before income tax	(1,256)	(676)	(3,600)	(7,834)
Income tax	-	-	-	-
Net loss	\$ (1,256)	\$ (676)	\$ (3,600)	\$ (7,834)
Basic and diluted loss per share:				
Net loss	\$ (0.07)	\$ (0.05)	\$ (0.22)	\$ (0.47)
Weighted average common shares outstanding:				
Basic and diluted	17,081	15,772	16,398	16,773



**PROPHASE LABS, INC. & SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEET DATA**  
**(in thousands)**

	<u>December 31, 2015</u>	<u>December 31, 2014</u>
Cash and cash equivalents	\$ 1,664	\$ 2,926
Accounts receivable, net	\$ 4,000	\$ 5,836
Inventory	\$ 4,331	\$ 3,292
Total current assets	\$ 11,879	\$ 13,458
Total assets	\$ 14,829	\$ 16,057
Total current liabilities	\$ 4,534	\$ 5,241
Total long term obligations	\$ 1,466	\$ 100
Total stockholders' equity	\$ 8,829	\$ 10,716

